Guido Verbeck at the Breath Biopsy Conference 2021

Early Detection session - The determination of breath biomarkers and metabolites for disease and health constituents using non-invasive direct inject mass spectrometry (20min)

 

The Breath Biopsy Conference 2022 is scheduled for 1st-3rd November. Click the button to express interest in the next Breath Biopsy Conference:

Express Interest

Talk Abstract:

Breath capture chemistry is a rising method of examining physiological information as a means to discover and track biomarkers and metabolites for clinical applications. Previous studies have highlighted the ability of breath samples to indicate presence of respiratory viral infections, such as Influenza A, MERS, SARS-CoV-1, and in our group SARS-CoV-2, through the detection of volatile chemical markers via mass spectrometry, typically with solid phase substrates. Due to its non-invasive sample collection and unlimited supply, further exploration of this volatile chemistry in the breath for a more detailed understanding of its connection to disease, diet, and general lifestyle is incredibly beneficial for the medical field, among others. Here we will present a rapid non-invasive breath capture techniques using the Teslin substrate for direct analysis with mass spectrometry. We then coupled this data with the analytics of partial-least squared discriminant analysis and K-nearest neighbor, and check with K-fold cross validation to confirm chemical assignments. These experiments are designed to exact the chemistry of the breath biomarker and metabolites, and help train more portable instruments on the chemicals of interest. Previous research will be shown as to the efficacy of this direct inlet mass spectrometry technique. For disease states, presence of drug metabolites, and lifestyle biomarkers, limits of detection and mass accuracy of this direct inject mass spectrometry will be presented.

Speaker Biography:

Dr Guido F. Verbeck, Professor of Chemistry and Biochemistry, is an expert is mass spectrometry, specifically instrument design and development. Guido Verbeck received his PhD as a Proctor & Gamble fellow in chemistry at Texas A&M University. Dr Verbeck has developed mass spectrometers over the past 20 years, and has been a member of the analytical community for 25 years. His appointment is at the University of North Texas where he continues to design novel ion optical devices for miniaturization, preparative, and analytical mass spectrometry, and is the Director for the Laboratory of Imaging Mass Spectrometry. In this appointment Dr Verbeck has received $5M in external funding, 85 peer reviewed publications, 10 awarded patents and 8 applications, and graduated 20 graduate students in instrument development. Guido Verbeck was awarded a Young Investigator Award from the Air Force Office of Scientific Research and the University of North Texas Early Career Award for Research Creativity. Dr Verbeck continues to develop new mass spectrometers specifically for single-cell analysis for cancer biomarkers, nanoparticle development for pharmaceutical and toxicological biochemical effects, and determining the biological mechanisms for biomolecular condensates.

The Breath Biopsy Conference 2022 is scheduled for 1st-3rd November. Click the button to express interest in the next Breath Biopsy Conference:

Express Interest